GlobeNewswire

Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)

Del
  • Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismutase 1 (SOD1) mutation
  • Late breaking interim data to be presented at the American Academy of Neurology Annual Meeting (AAN) show a statistically significant reduction in SOD1 protein levels and a numerical trend towards slowing of clinical decline in SOD1-ALS patients treated with tofersen
  • Biogen recently initiated VALOR, a phase 3 clinical trial to confirm the efficacy and safety of tofersen in SOD1-ALS patients

CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today interim results of a phase 1/2 study of tofersen, an antisense oligonucleotide (ASO) being studied for the potential treatment of amyotrophic lateral sclerosis (ALS) in adults with a confirmed superoxide dismutase 1 (SOD1) mutation. The data will be presented at the American Academy of Neurology Annual Meeting (AAN) in Philadelphia, PA (May 4-10, 2019).

“The interim results of this study, which achieved proof-of-biology and proof-of-concept, support the initiation of a phase 3 clinical trial to confirm the efficacy and safety of tofersen in SOD1-ALS patients and further demonstrate the potential of ASOs to target the genetic driver of disease,” said Michael Ehlers, M.D., Ph.D., executive vice president, research and development at Biogen. “We are committed to bringing a potential breakthrough therapy to patients with ALS and we are expediting our efforts with the aim of addressing this urgent unmet need.”

The Phase 1/2 study of tofersen in SOD1-ALS is a randomized, placebo-controlled, single- and multiple-ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy endpoints of tofersen in 70 patients with ALS. In the multiple ascending dose portion of the study, 50 participants with SOD1 mutations were randomized to receive tofersen (20 mg, 40 mg, 60 mg, or 100 mg) or placebo for 12 weeks.

In the interim analysis, treatment with tofersen 100 mg (n=10) over a three-month period resulted in a statistically significant lowering of SOD1 protein levels in the cerebrospinal fluid (p=0.002) and a numerical trend towards slowing of clinical decline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), slow vital capacity and muscle strength compared to placebo (n=12). Specifically, the mean change in ALSFRS-R score from baseline to Day 85 was -1.1 in the tofersen 100 mg group compared to -5.3 in the placebo group, on a 48-point scale. Across clinical measures, separation from the placebo group was most apparent in patients with fast progressing disease. The safety and tolerability profile in this analysis supports continued development of tofersen in ALS. The data will be presented by study co-principal investigator Timothy M. Miller, M.D., Ph.D., of the Washington University School of Medicine in St. Louis, MO on May 7, 2019 at 11:45 a.m. ET as a late breaking oral presentation.

“ALS is a devastating disease and there are currently no therapeutic options that reliably slow or halt its rapid progression,” said Merit Cudkowicz, M.D., co-principal investigator and the director of the Healey Center at Massachusetts General Hospital. “We are encouraged by the positive results of this phase 1/2 study of tofersen in patients with SOD1-ALS and are excited to advance this clinical program to a phase 3 trial to further investigate its therapeutic potential.”

In March 2019 the first patient was dosed in the Phase 3 VALOR study of tofersen in adults with ALS with a confirmed SOD1 mutation. The VALOR study aims to assess the efficacy and safety of tofersen versus placebo. The primary endpoint of this study is an analysis based on the ALSFRS-R score, which is a validated rating instrument that monitors the progression of disability in patients with ALS. Biogen is collaborating with regulators to further define the scope of the clinical data package required to support the registration of tofersen.

ALS is a rare and fatal neurodegenerative disease characterized by motor neuron loss in the brain and spinal cord that is responsible for controlling voluntary muscle movement. Symptoms may vary depending on the location of the motor neuron failure and may include limb weakness, difficulty breathing and trouble speaking and swallowing. There is a growing body of evidence that mutations within multiple genes are believed to cause ALS. ALS with SOD1 mutations is a rare subtype of familial ALS and accounts for approximately two percent of all ALS cases.

About tofersen
Tofersen is an antisense oligonucleotide (ASO) being developed for the treatment of ALS with SOD1 mutations. Tofersen binds to SOD1 mRNA, allowing for its degradation by RNase-H and reduction of SOD1 protein production. This is thought to decrease the toxicity of mutant SOD1 and potentially provide therapeutic benefit through improved survival and function to people with ALS with SOD1 mutations. Tofersen demonstrated proof-of-biology and proof-of-concept in a Phase 1/2 study. Biogen licensed tofersen from Ionis Pharmaceuticals, Inc. under a collaborative development and license agreement.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – TwitterLinkedInFacebookYouTube.

Biogen Safe Harbor Statement
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about results from the Phase 1/2 study of tofersen; the potential clinical effects of tofersen; the potential benefits, safety and efficacy of tofersen; the clinical development program for tofersen; the potential of our commercial business and pipeline programs, including tofersen; the anticipated benefits and potential of our collaboration arrangements with Ionis; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation, uncertainty of success in the development and potential commercialization of tofersen; the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected; unexpected concerns may arise from additional data, analysis or results obtained during our clinical trials; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, including tofersen; the occurrence of adverse safety events; the risks of other unexpected hurdles, costs or delays; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release.

We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

MEDIA CONTACT:

David Caouette  
+1 617 679 4945
public.affairs@biogen.com 
INVESTOR CONTACT:

Mike Hencke
+1 781 464 4471
IR@biogen.com 

 

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Fortuna CEO purchases company shares17.5.2019 21:00:00 CESTPressemelding

VANCOUVER, British Columbia, May 17, 2019 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that Jorge A. Ganoza, Chief Executive Officer of the Company, has increased his equity position in the Company by acquiring 170,000 common shares on the open market at an average price of US$2.59 per share. An insider report filing reflecting the share acquisition has been made on the SEDI website at www.sedi.ca. About Fortuna Silver Mines Inc. Fortuna is a growth oriented, precious metal producer with its primary assets being the Caylloma silver mine in southern Peru, the San Jose silver-gold mine in Mexico and the Lindero gold Project, currently under construction, in Argentina. The Company is selectively pursuing acquisition opportunities throughout the Americas and in select other areas. For more information, please visit its website at www.fortunasilver.com. ON BEHALF OF THE COMPANY Carlos Baca Investor Relations Manager Trading symbols: NYSE: FSM | TSX: FVI Inves

Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel17.5.2019 15:25:00 CESTPressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 17, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it welcomes the updated Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019, published by the U.S. Centers for Disease Control and Prevention (CDC)1. These guidelines increase the focus on eradicating tuberculosis (TB) disease in the United States through an individual risk-based approach to screening and treatment for Healthcare Personnel (HCP). Key highlights from the updated guidelines include: Recommendation for TB Screening and Individual Based TB Risk Assessment on Hire : continue baseline screening of all HCPs upon hire with the addition of an individual risk assessment Recommendation to Focus Serial Testing on Higher Risk Individuals: decision to perform TB testing afte

First Dolby Cinema Opens in Germany with Kinopolis Gruppe in Munich17.5.2019 14:30:00 CESTPressemelding

MUNICH, Germany, May 17, 2019 (GLOBE NEWSWIRE) -- Dolby Laboratories, Inc. (NYSE:DLB) and Kinopolis Gruppe today announced the opening of the first Dolby Cinema in Germany at the renowned Mathäser Palast in Munich. Film fans can now enjoy the very best cinema presentation in the heart of the city, following the opening of the highly-anticipated site. Dolby Cinema combines Dolby Vision, Dolby Atmos, and bespoke design to create the perfect environment to be fully immersed in the storytelling of a film. Dolby Vision is presented through a dual 4K laser, High Dynamic Range (HDR) projector system, and boasts a spectacular, ultra vivid picture. Compared to standard screens, the Dolby Vision image is twice as bright, 500 times the contrast ratio, has blacker blacks, and an unsurpassed colour palette. Cutting-edge Dolby Atmos sound transports viewers into the scene, filling the cinema with a soundscape that flows all around and above the audience. Dolby works with each cinema location to crea

Four Progressive Leaders to Receive the 2019 YPO Global Innovation Awards  17.5.2019 08:00:00 CESTPressemelding

Thirst CEO Mina Guli, RaySearch Laboratories AB CEO Johan Löf, Malwarebytes CEO Marcin Kleczynski & Apeel CEO James Rogers honored NEW YORK, May 17, 2019 (GLOBE NEWSWIRE) -- YPO, the premier global leadership organization for more than 27,000 chief executives, today announced the winners of its prestigious Global Innovation Awards. Presented in conjunction with YPO Innovation Week, the Global Innovation Awards annually recognizes YPO members who are making an impact through transformation around the globe in four categories: Social Impact, Medical, Technology, and Manufacturing. “Our goal for the 2019 Global Innovation Award winners is to recognize YPO member companies that are creating scalable solutions which address challenges both at a local and/or global level,” said Mohamed Alkady, YPO Global Innovation Awards Chair. “Each of these winners represent their category with glaring leadership and, most importantly, a clear mission and vision. This extraordinary group have demonstrated

Dr. Deep Saini appointed as Dalhousie University’s 12th President16.5.2019 21:09:00 CESTPressemelding

Halifax, NS, May 16, 2019 (GLOBE NEWSWIRE) -- Dalhousie University’s Board of Governors announced today that Dr. Deep Saini has been appointed as the university’s 12th President and Vice-Chancellor. Dr. Saini, who is currently Vice-Chancellor and President of the University of Canberra in Australia, was the unanimous choice of the search committee. He is an accomplished leader who combines significant Canadian post-secondary experience with a global outlook; a distinguished scientist whose belief in the transformative power of education has defined his life’s journey; and a warm, genuine and inspiring individual ready to build on Dal’s 200 years of achievement and chart a course towards even greater success in our third century ahead. “I am honoured and humbled by the opportunity to serve as the 12th President and Vice-Chancellor of Dalhousie University,” says Dr. Saini. “The university’s singular commitment to its anchor role in the region’s economic and social development is fittingl

PureCircle and Merisant Renew Stevia Supply Agreement16.5.2019 18:00:00 CESTPressemelding

Leading Tabletop Sweetener Company Will Increase Its Purchases of Great-Tasting Ingredients From Top Global Stevia Supplier CHICAGO, May 16, 2019 (GLOBE NEWSWIRE) -- PureCircle (LSE: PURE), the world’s leading producer and innovator of stevia sweeteners, has entered into a new stevia supply agreement with Merisant, one of the world’s leading producers of low- and zero-calorie tabletop sweeteners for consumers. This new and expanded partnership will help to ensure Merisant’s long-term supply of the best-tasting stevia ingredients. Merisant has been a partner and customer of PureCircle for the last ten years. Merisant’s sweetener products are sold in more than 90 countries worldwide. This new agreement focuses on the supply to Merisant of PureCircle’s next generation stevia sweetener ingredients like Reb M. PureCircle announced last year that it significantly increased its capacity to supply Reb M to consumer product companies. PureCircle’s Reb M is a next generation zero-calorie sweeten